Comparative Pharmacology
Head-to-head clinical analysis: KLONOPIN RAPIDLY DISINTEGRATING versus LORAZEPAM INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLONOPIN RAPIDLY DISINTEGRATING versus LORAZEPAM INTENSOL.
KLONOPIN RAPIDLY DISINTEGRATING vs LORAZEPAM INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine; enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
0.5 mg to 2 mg orally twice daily for anxiety; 0.5 mg to 1 mg orally three times daily for panic disorder. Maximum dose: 4 mg/day for panic disorder.
0.5-2 mg orally every 6-8 hours as needed. Maximum 4 mg/day.
None Documented
None Documented
Terminal half-life 30-40 hours (range 19-60 h) in adults; accumulation occurs with repeated dosing, steady-state reached in 5-7 days.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in elderly (15-20 hours) and patients with hepatic impairment (up to 30-40 hours).
Renal (60-80% as metabolites, mainly glucuronide conjugates; <2% as unchanged drug). Biliary/fecal excretion accounts for ~10-20%.
Renal excretion of glucuronide conjugates; <1% unchanged drug excreted renally. Fecal elimination accounts for approximately 10% of administered dose.
Category C
Category D/X
Benzodiazepine
Benzodiazepine